Citius Pharmaceuticals Inc. (NASDAQ:CTXR) has completed the Boston Analytical study “Silicone Disk Method for In Vitro Assessment of Antimicrobial Activity Against Resistant Staphylococcal Biofilms by Minocycline-EDTA-Ethanol and EDTA-Ethanol Lock Solutions.”
Mino-Lok components more effective compared to EDTA/ethanol
The study showed that the three Mino-Lok components (30 mg/mL EDTA, 1 mg/mL minocycline, and 19.5% ethanol) were superior compared to EDTA/ethanol. The company used the two Staphylococcus aureus strains for inocula and also tested two samples of each strain as four reference groups. Also, they assessed the test solutions after incubation for three-time points of 60 90, and 120 minutes. Citius assessed Colony Forming Units/Disk value from ten disks at every timer point for all groups.
Results of the study showed that the CFU-Disk number during the 60 minutes exposure under the MLT group was almost significant compared to CFU/Disk in the EDTA/ethanol group in one strain and was close to significance in the second strain. Interestingly in all the exposures, the CFU/Disk number was lower in the MLT group relative to the treated disks in the EDTA/ethanol group.
Mino-Lok has demonstrated effectiveness in eradicating Candida parapsilosis
According to researchers, when the results are taken together they indicate that MLT can eradicate the biofilm quickly compared to EDTA/ethanol. Citius CE, Myron Holubiak stated that Staphylococcus aureus is a worrisome pathogen common in catheter-related bloodstream infections. Myron said that the pathogen gets special consideration in the IDSA guidelines in CRBSI treatment and therefore Citius is delighted that demonstrate that Mino-Lok can be effective and work expeditiously compared to ethanol. He added that earlier studies have shown that Mino-Lok components can eradicate Candida parapsilosis and MRSA.
Recently the company demonstrated the effectiveness of MLT in vitro against ten Candida Auris strains. Most importantly all the pathogens are of concern for cancer patients having central lines. Myron said that as the company approaches its finals stages they are delighted to release the results of the pivotal study on Mino-Lok. Citius has designed the study to demonstrate Mino-Lok’s superiority relative to standard antibiotic locks.
